- Home
- STT vs BDX Comparison
STT vs BDX Comparison
Compare STT & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STT | BDX |
|---|---|---|
| Founded | 1792 | 1897 |
| Country | United States | United States |
| Employees | 50596 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6B | 43.0B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | STT | BDX |
|---|---|---|
| Price | $187.05 | $170.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $148.86 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | 2.23% | ★ 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $7.66 | N/A |
| Revenue Next Year | $3.87 | $3.02 |
| P/E Ratio | ★ $13.80 | $674.88 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $104.64 | $140.11 |
| 52 Week High | $192.51 | $213.08 |
Technical Indicators
Market Signals| Indicator | STT | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 63.91 | 65.56 |
| Support Level | $175.50 | $163.44 |
| Resistance Level | $192.51 | $196.05 |
| Average True Range (ATR) | 4.32 | 3.81 |
| MACD | -0.36 | 1.07 |
| Stochastic Oscillator | 96.22 | 88.05 |
Price Performance
Historical ComparisonAbout STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $54 trillion in assets under custody and administration, and $5.7 trillion in assets under management, as of Dec. 31, 2025, State Street operates globally in more than 100 geographic markets and employs about 51,500 worldwide.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.